Journal of equine veterinary science · 2026
Periovulatory administration of therapeutic and supratherapeutic doses of firocoxib does not impair induced ovulation or follicular dynamics in mares treated with a GnRH analogue.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Faria L G, Zutter B M, Freitas-Dell'Aqua C P, Camillo B L, Ávila-Júnior O S, Bassetti F S, Marcolino L C, Alvarenga M A
Аннотация
OBJECTIVE: To evaluate the effects of therapeutic and supratherapeutic periovulatory doses of firocoxib on ovulation and follicular dynamics in mares.
MATERIALS AND METHODS: Seventy cycling mares were randomly assigned to receive firocoxib at 0.1 mg/kg (n = 27), firocoxib at 0.3 mg/kg (n = 22), or no treatment (control; n = 21). Treatments were initiated on Day 0, defined as the day of ovulation induction with a GnRH analogue administered intramuscularly, with firocoxib administered intravenously on Day 0 and Day 1 (24 h apart). Follicular diameter and ovulation timing were assessed by transrectal ultrasonography.
RESULTS: All mares ovulated within 72 h after ovulation induction, with no ovulatory failures or hemorrhagic anovulatory follicles. Time to ovulation did not differ among groups (P > 0.05). Dominant follicle diameter on Days -2 and -1 and percentage follicular growth between these days were similar across treatments (P > 0.05).
CONCLUSIONS: Periovulatory administration of firocoxib, even at supratherapeutic doses, did not appear to impair induced ovulation or follicular development in mares under the conditions of this study.
MATERIALS AND METHODS: Seventy cycling mares were randomly assigned to receive firocoxib at 0.1 mg/kg (n = 27), firocoxib at 0.3 mg/kg (n = 22), or no treatment (control; n = 21). Treatments were initiated on Day 0, defined as the day of ovulation induction with a GnRH analogue administered intramuscularly, with firocoxib administered intravenously on Day 0 and Day 1 (24 h apart). Follicular diameter and ovulation timing were assessed by transrectal ultrasonography.
RESULTS: All mares ovulated within 72 h after ovulation induction, with no ovulatory failures or hemorrhagic anovulatory follicles. Time to ovulation did not differ among groups (P > 0.05). Dominant follicle diameter on Days -2 and -1 and percentage follicular growth between these days were similar across treatments (P > 0.05).
CONCLUSIONS: Periovulatory administration of firocoxib, even at supratherapeutic doses, did not appear to impair induced ovulation or follicular development in mares under the conditions of this study.